Anthera Pharmaceuticals: Researching and Developing Therapeutics for Unmet Medical Needs

There are not that many companies which have invested in creating therapeutics for autoimmune diseases. Anthera Pharmaceuticals is one of the companies that have invested on their research and development division to address these diseases as well as those related to inflammation.

The company has been around since 2004 and is now listed as a component of the Wilshire 5000 Index. It is traded publicly on the NASDAQ and markets its common stocks under the ticker symbol ANTH. The lead product of the business is currently being developed and is currently in late stages of clinical studies. This product is named as the A-623 and is intended for IgA nephropathy and systemic lupus erythematosus. By acquiring one of the clinical trials of Eli Lilly and Company, Anthera Pharmaceuticals got the Sollpura which is being investigated for pancreatic enzyme replacement therapy (PERT).

By continually advancing and investing in their research and development, the company continues to provide hope to patients with life-threatening diseases. It is in Hayward, California that the company holds its corporate office.